EnteroMedics News

The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.

Together, we are all trying to build our fortune by finding well-run companies at bargain-basement prices.

Imperial Sugar Co., Cargill Inc. and a cane growers group have agreed to jointly build a refinery valued at about $90 million in Gramercy, La.

Ecolab : Posted third-quarter net income of $145 million and revenue of $1.55 billion, vs.

EnteroMedics, a US-based medical device company, has implemented a plan to reduce its workforce and operating costs in order to preserve capital and streamline its operations following the announcement of topline results from its pivotal Empower study on October 2, 2009.

Our analysts have issued complimentary analysis on the following six companies: Trident Microsystems Inc.

Ecolab Inc. , St. Paul, has entered into an exclusive relationship with Tennant Co.

EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today reported financial results for the three and nine months ended September 30, 2009.

E nteroMedics Inc. said Friday that results from a pivotal clinical trial failed to meet key endpoints, or goals, intended to prove that its anti-obesity device was effective as a treatment to encourage weight loss.

EnteroMedics Inc., a Roseville-based start-up that is developing an obesity-fighting device, said this morning that preliminary results from a pivotal study did not meet its primary and secondary endpoints that determine whether or not the product is effective.

Minneapolis / St. Paul Business Journal - by Katharine Grayson and Jennifer Niemela Staff Writer EnteroMedics Inc.

Oct. 3--Now what? After years of study and tens of millions spent in development, Roseville-based EnteroMedics announced Friday that its implantable device to treat obesity was found to be ineffective in a key trial.

EnteroMedics said on Friday that its implantable weight-loss device failed in a study.

EnteroMedics Inc., , the developer of medical devices using neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders, today announced that it has entered into a definitive agreement with an institutional investor to sell 6,161,068 of the Company's common shares in a "registered direct" offering, ...

ST. PAUL, Minn. - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced preliminary results from its EMPOWER Study.

PAUL, Minn.-- --EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announc... 09/24/2009 - 04:01 PM MINNEAPOLIS-- --Christopher & Banks Corporation today announced that its Board of Directors has declared a quarterly cash dividend of $0.06 per share, to be ...

ST. PAUL, Minn. - EnteroMedics Inc. , the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it was added to the Russell 3000 Index on June 26, 2009.

I would like to recommend EnteroMedics, ticker "ETRM".A A great little company -A world class management and governance, diamond in the rough entity that is developing a device for obesity that may change the paradigm of treating this ballooning epidemic.A I travel a bit, but will certainly put forth a pitch inA the coming days once I see theA ...